• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Perioperative Systemic Chemotherapy in Patients with Malignant Peritoneal Mesothelioma Undergoing Cytoreduction and HIPEC: Don't Put the Cart Before the Horse.

作者信息

Alexander H Richard

机构信息

Division of Surgical Oncology, Department of Surgery, Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.

出版信息

Ann Surg Oncol. 2023 Oct;30(11):6301-6303. doi: 10.1245/s10434-023-13783-y. Epub 2023 Jun 26.

DOI:10.1245/s10434-023-13783-y
PMID:37358682
Abstract
摘要

相似文献

1
Perioperative Systemic Chemotherapy in Patients with Malignant Peritoneal Mesothelioma Undergoing Cytoreduction and HIPEC: Don't Put the Cart Before the Horse.接受细胞减灭术和腹腔热灌注化疗的恶性腹膜间皮瘤患者的围手术期全身化疗：勿本末倒置。
Ann Surg Oncol. 2023 Oct;30(11):6301-6303. doi: 10.1245/s10434-023-13783-y. Epub 2023 Jun 26.
2
A case report of hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) for malignant peritoneal mesothelioma.恶性腹膜间皮瘤术中腹腔热灌注化疗（HIPEC）的病例报告
Asian J Surg. 2023 Dec;46(12):5747-5748. doi: 10.1016/j.asjsur.2023.08.119. Epub 2023 Aug 30.
3
ASO Author Reflections: International Standardization of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Protocols-Malignant Peritoneal Mesothelioma as a Model.ASO作者反思：腹腔热灌注化疗（HIPEC）方案的国际标准化——以恶性腹膜间皮瘤为模型
Ann Surg Oncol. 2023 Nov;30(12):7858-7859. doi: 10.1245/s10434-023-14120-z. Epub 2023 Aug 25.
4
ASO Author Reflections: Perioperative Systemic Chemotherapy in Diffuse Malignant Peritoneal Mesothelioma treated with CRS-HIPEC.ASO作者反思：采用CRS-HIPEC治疗的弥漫性恶性腹膜间皮瘤的围手术期全身化疗
Ann Surg Oncol. 2024 Apr;31(4):2511-2512. doi: 10.1245/s10434-023-13768-x. Epub 2024 Jan 13.
5
Delayed CRS-HIPEC Is Associated with Decreased Survival in Patients with Malignant Peritoneal Mesothelioma: A Markov Decision Analysis.延迟性细胞减灭术联合腹腔热灌注化疗与恶性腹膜间皮瘤患者生存率降低相关：一项马尔可夫决策分析
J Gastrointest Surg. 2023 May;27(5):995-997. doi: 10.1007/s11605-022-05540-5. Epub 2022 Nov 28.
6
Impact of Perioperative Systemic Chemotherapy on Survival for Patients Who have Diffuse Malignant Peritoneal Mesothelioma Treated with CRS-HIPEC.腹腔热灌注化疗治疗弥漫性恶性腹膜间皮瘤患者的围手术期全身化疗对生存的影响。
Ann Surg Oncol. 2024 Jan;31(1):556-566. doi: 10.1245/s10434-023-13640-y. Epub 2023 Nov 8.
7
Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome.反复进行的细胞减灭术及腹腔热灌注化疗治疗复发性或进展性弥漫性恶性腹膜间皮瘤：临床病理特征及生存结果
Ann Surg Oncol. 2015 May;22(5):1680-5. doi: 10.1245/s10434-014-3977-y. Epub 2014 Aug 14.
8
Long-Term Survival in Patients Treated with Cytoreduction and Heated Intraperitoneal Chemotherapy for Peritoneal Mesothelioma at a Single High-Volume Center.单家高容量中心行细胞减灭术联合腹腔热灌注化疗治疗腹膜间皮瘤的长期生存结果。
Ann Surg Oncol. 2023 May;30(5):2666-2675. doi: 10.1245/s10434-022-13061-3. Epub 2023 Feb 8.
9
Ten-year single-center experience with treatment of primary diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).十年单中心经验：细胞减灭术（CRS）和腹腔热灌注化疗（HIPEC）治疗原发性弥漫性恶性腹膜间皮瘤（DMPM）。
Langenbecks Arch Surg. 2022 Nov;407(7):3057-3067. doi: 10.1007/s00423-022-02594-6. Epub 2022 Jun 23.
10
The Role of Ki-67 and Pre-cytoreduction Parameters in Selecting Diffuse Malignant Peritoneal Mesothelioma (DMPM) Patients for Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).Ki-67和术前减瘤参数在选择弥漫性恶性腹膜间皮瘤（DMPM）患者进行减瘤手术（CRS）和腹腔内热灌注化疗（HIPEC）中的作用。
Ann Surg Oncol. 2016 May;23(5):1468-73. doi: 10.1245/s10434-015-4962-9. Epub 2015 Nov 16.

本文引用的文献

1
Expression of PD-L1 in Patients With Malignant Peritoneal Mesothelioma: A Pilot Study.恶性腹膜间皮瘤患者 PD-L1 的表达：一项初步研究。
J Surg Res. 2022 Sep;277:131-137. doi: 10.1016/j.jss.2022.04.005. Epub 2022 Apr 27.
2
Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma.晚期恶性腹膜间皮瘤中 PD-L1（阿特珠单抗）和 VEGF（贝伐珠单抗）联合阻断的疗效、安全性和生物标志物分析。
Cancer Discov. 2021 Nov;11(11):2738-2747. doi: 10.1158/2159-8290.CD-21-0331. Epub 2021 Jul 14.
3
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
一线纳武利尤单抗联合伊匹单抗治疗不可切除恶性胸膜间皮瘤（CheckMate 743）：一项多中心、随机、开放标签、III 期临床试验。
Lancet. 2021 Jan 30;397(10272):375-386. doi: 10.1016/S0140-6736(20)32714-8. Epub 2021 Jan 21.
4
Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy.恶性腹膜间皮瘤患者接受全身或腹腔化疗时 PD-L1 表达的异质性。
Br J Cancer. 2021 Feb;124(3):564-566. doi: 10.1038/s41416-020-01130-x. Epub 2020 Oct 26.
5
The impact of chemotherapy and its timing on survival in malignant peritoneal mesothelioma treated with complete debulking.根治性细胞减灭术治疗恶性腹膜间皮瘤中化疗及其时机对生存的影响。
Med Oncol. 2018 Apr 12;35(5):69. doi: 10.1007/s12032-018-1125-4.
6
Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study.弥漫性恶性腹膜间皮瘤：通过 RENAPE 数据库评估全身化疗联合综合治疗的疗效：多中心回顾性研究。
Eur J Cancer. 2016 Sep;65:69-79. doi: 10.1016/j.ejca.2016.06.002. Epub 2016 Jul 26.
7
The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.细胞减灭术和腹腔内热灌注化疗治疗弥漫性恶性腹膜间皮瘤患者围手术期全身化疗的作用。
Ann Surg Oncol. 2013 Apr;20(4):1093-100. doi: 10.1245/s10434-012-2845-x. Epub 2013 Mar 2.
8
Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent.恶性腹膜间皮瘤——国际扩大可及项目中使用培美曲塞单药或联合铂类药物的结果。
Lung Cancer. 2009 May;64(2):211-8. doi: 10.1016/j.lungcan.2008.08.013. Epub 2008 Nov 29.
9
Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program.培美曲塞单药或联合顺铂治疗腹膜间皮瘤患者的开放标签研究：扩大可及项目的结果
Clin Lung Cancer. 2005 Jul;7(1):40-6. doi: 10.3816/CLC.2005.n.020.
10
Treatment of peritoneal mesothelioma with radioactive colloidal gold; report of a case.放射性胶体金治疗腹膜间皮瘤；病例报告
Cancer. 1955 May-Jun;8(3):478-81. doi: 10.1002/1097-0142(1955)8:3<478::aid-cncr2820080307>3.0.co;2-4.